Building upon research at the Gladstone Institutes, Tenaya Therapeutics, a new biopharmaceutical company, will concentrate on regenerative medicine and drug finding for cardiovascular diseases. The new company is supported by fifty dollars million in Series A financing from The Column Team. JJ Kang, Ph. D., an associate at The Column Team, is the president of the new company.
Tenaya is the first company to be created from BioFulcrum, the entrepreneurial initiative within Gladstone, that started in January, 2015. The newest company plans to leverage Gladstone’ s work with mobile reprogramming in their research, including regenerating heart muscles plus creating stem-cell derived heart models for pharmaceutical growth.